Move over, Novartis: Kite and Gilead break into CAR-T market with early axi-cel nod
admin 18th October 2017 Uncategorised 0Today, the FDA approved Kite’s CAR-T, axicabtagene ciloleucel, about six weeks earlier than expected, vaulting Kite and its soon-to-be-parent Gilead into a market first launched by Novartis—and its hefty price tag will no doubt pull axi-cel into the ongoing debate over high drug prices.
More: Move over, Novartis: Kite and Gilead break into CAR-T market with early axi-cel nod
Source: fierce